Hemodynamic and endocrine factors are among the most important factors implicated in the physiology and pathophysiology of the vascular wall. Arterial hypertension evokes structural and functional changes of the vascular wall (1, 2). Modifications of the extracellular matrix, including fibronectin (FN) 1 and collagen, have been previously reported in vessel walls of hypertensive animals (3-5). Activation and qualitative changes in the extracellular matrix participate in vascular wall remodeling and in the pathogenesis of atherosclerosis. Vascular remodeling in hypertension may be an adaptive response to increased transmural pressure (6 -9). Mechanical stress seems to play a direct role in vascular remodeling, since mechanical stretch is able to increase protein synthesis by vascular smooth muscle cells (VSMCs) (10). However, neuronal and humoral factors may be critical in hypertension-induced remodeling of vascular wall. Especially, several in vivo studies have reported that hypertension activates the vascular renin-angiotensin system (RAS) including angiotensin-converting enzyme (ACE) (11), and infusion of pressor and subpressor doses of angiotensin II (Ang II) increases aortic FN mRNA in both hypertensive and normotensive animals (12, 13). Ang II evokes diverse physiological response including arterial vasoconstriction to elevate blood pressure in vivo (14) and increases production of collagen with a growth-promoting effect on VSMCs in vitro (15). Pharmacological evidence has defined at least two subtypes of Ang II receptors, Ang II type 1 (AT1) receptor and Ang II type 2 (AT2) receptor. Previous results of molecular cloning have revealed that both receptor subtypes belong to the superfamily of G protein-coupled receptors with seven transmembrane helices (16 -19). According to the recent results of in vitro studies, Ang II initially activates a phosphatidylinositol-specific phospholipase C (PI-PLC) via its binding to AT1 receptor on the surface of VSMCs, leading to the generation of inositol triphosphate and diacylglycerol (20), which are involved in intracellular Ca 2ϩ mobilization (21) and protein kinase C (PKC) activation (22), respectively. In VSMCs, Ang II also induces a rapid increase in expression of the growth-associated nuclear protooncogenes and stimulates tyrosine phosphorylation of multiple substrates (23, 24). These findings, taken together with relatively abundant expression of AT1 receptor in vascular wall and VSMCs, indicate that Ang II plays an important role in vascular remodeling via an AT1 receptor pathway. Thus, investigation of the mechanism of Ang II-induced regulation of extracellular matrix and tissue RAS in VSMCs is essential in elucidating the mechanism of vascular remodeling and the pathogenesis of atherosclerosis.In the present study, we examined the effects of Ang II on gene expression of extracellular matrix components (FN and
Angiotensinogen is expressed in many tissues besides the liver. Recent studies have suggested that abnormalities in the regulation of angiotensinogen gene expression may be involved in the development of hypertension. However, little information is available concerning the functional significance of tissue angiotensinogen. In this study, we measured plasma angiotensinogen concentration by radioimmunoassay and examined the expression of tissue angiotensinogen by Northern blot analysis in spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY). Although plasma angiotensinogen concentration in SHR was comparable to that in WKY at 6 weeks of age, it was increased significantly at 14 weeks of age in SHR and became higher than that in WKY. The levels of hepatic angiotensinogen mRNA were similar in SHR and WKY, and the levels of aortic, adrenal, and renal angiotensinogen mRNAs were lower in SHR than in WKY at both 6 and 14 weeks of age. Brain angiotensinogen expression in SHR was higher than in WKY at 6 weeks of age and was comparable to that in WKY at 14 weeks of age. On the other hand, cardiac and fat angiotensinogen mRNA levels were significantly increased at 14 weeks of age in SHR. These results demonstrate that the expression of tissue angiotensinogen is regulated differently in SHR and WKY and indicate that the development of hypertension is accompanied at least temporally with increases in plasma angiotensinogen concentration as well as cardiac and adipogenic angiotensinogen mRNA in SHR.
These results demonstrate that the expression of tissue angiotensinogen, AT1 and fibronectin mRNAs is regulated differently in Dahl Iwai salt-sensitive and salt-resistant rats, and indicate that salt-mediated hypertension activates the cardiac fibronectin gene independently of the tissue renin-angiotensin system and stimulates the aortic fibronectin gene with activation of the tissue renin-angiotensin system.
We compared interleukin-6 (IL-6) removal and induction between conventional polysulfone (Con) and TORAYLIGHT NV (NV) dialyzers in hemodialysis patients. Twenty patients on Con with high IL-6 concentrations (2.7-8.5 pg/mL) were randomized to Con or NV group. Dialyzer performance was determined in NV group while patients were on Con and after being switched onto NV. Erythropoiesis-stimulating agent (ESA) response index (ERI) was assessed every 4 months for one year. IL-6 clearance was comparable between Con and NV. IL-6 removal rates were comparable for the first 1 h, but were higher with NV for the entire session (P = 0.03). Before-to-during-dialysis IL-6 concentration ratios were lower with NV on the venous side after the session (P = 0.03). During the one-year study, hemoglobin was lower in Con group than in NV group at month 8 (P = 0.046). ERI decreased in NV and increased in Con group, with a significant difference between the groups (P = 0.002). NV and Con are comparable in removing IL-6 and both induce IL-6. However, the data suggest that NV induces less IL-6, which may reduce the risk of ESA hyporesponsiveness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.